ArticleAnnals of pediatric cardiology
Effects of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, on renal impairment in patients with cyanotic congenital heart disease.
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances and unmet needs in pharmacologic therapy for pediatric heart failure: Insights from the 2025 International Society for Heart and Lung Transplantation Guidelines.Annals of pediatric cardiologyArticle
- Challenges in managing pediatric heart failure, especially in resource-limited settings.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) is widely used to manage heart failure, a common complication in patients with cyanotic congenital heart disease (CCHD). Its effects on the kidneys, especially in patients with long-standing cyanosis, remain poorly understood. We report three cases of CCHD who were started on ARNI for ventricular dysfunction. During treatment, all three developed features of cyanotic nephropathy. The discontinuation of ARNI led to a gradual improvement in renal function in all cases. This highlights a possible correlation between the use of ARNI and compromised renal parameters in patients with CCHD. Further studies are necessary to evaluate the renal safety and long-term effects of ARNI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.